Final NICE no for Shire’s pancreatic cancer drug
Pancreatic cancer patients will not be able to get routine access to Shire’s Onivyde on the National Health Service following a final rejection from cost regulators
Read More
Tag: Onivyde
SMC welcomes Roche’s Gazyvaro but rejects Shire’s Onivyde
Patients with follicular lymphoma in Scotland have gained a new treatment option for the condition after the Scottish Medicines Consortium (SMC) published advice accepting Roche’s Gazyvaro for routine use by NHS Scotland. On the downside, funding for Shire’s Onivyde to treat pancreatic cancer was rejected.
Read More
Ipsen to buy cancer drugs from Merrimack
French drugmaker Ipsen has entered into a definitive agreement to buy the global oncology assets from the USA’s Merrimack Pharmaceuticals, in a deal that could be worth around $1 billion.
Read More
NICE rejects Shire’s pancreatic cancer drug
Shire’s Onivyde has been turned down by the National Institute for Health and Care Excellence as an NHS-funded treatment for pancreatic cancer.
Read More
EU green light for Shire’s pancreatic cancer drug Onivyde
The European Medicines Agency has now issued a green light for Shire’s pancreatic therapy Onivyde, following its US approval in July this year.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
